The primary objective of this study is to determine the safety of the selegiline concurrent with dmethamphetamine challenges of 15 mg and 30 mg i.v. The primary outcome measures are cardiovascular responses (HR, BP) to the i.v. methamphetamine challenges.
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.